The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025

Tuesday, October 23, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Oct. 22, 2018 /PRNewswire/ --Human Chorionic Gonadotropin (hCG) Market by Technology (Natural Source Extraction, and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, and Others), and End User (Fertility Clinics, Research Institutes, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2025

Download the full report: Human Chorionic Gonadotropin (hCG) Market Overview :The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million
in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025. hCG hormone supports the normal development of an egg in a woman's ovary and stimulates the release of the egg during ovulation. It can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology. It is widely being used to treat infertility-related problems in women as well as increase sperm count in men. Moreover, it is used to treat cryptorchidism in young boys, a condition when the testicles have not dropped down into the scrotum normally.Significant surge in infertility issues among men & women and increase in prevalence of hypogonadism in geriatric population drive the growth of the global hCG market. In addition, increase in awareness toward hCG among healthcare professionals and patients fuels the market growth. However, availability of substitutes and cautions & warnings issued by FDA against the side effects of hCG hamper the growth of the market. On the contrary, rise in popularity of fertility tourism and availability of advanced IVF facilities & treatment options are expected to provide lucrative opportunities for the market in the near future.The global hCG market is segmented based on technology, therapeutic area, end user, and region. By technology, the market is bifurcated into natural source extraction and recombinant technology. Based on therapeutic area, it is classified into female infertility treatment, oligospermic treatment, male hypogonadism, and others. Depending on end user, it is segregated into fertility clinics, research institutions, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.Key Benefits for Human Chorionic Gonadotropin (hCG) Market :The study provides an in-depth analysis of the global human chorionic gonadotropin (hCG) market along with the current trends and future estimations to elucidate the imminent investment pockets.A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.A qualitative analysis of driving factors and opportunities helps analyze the competitive scenario of the market.Porter's Five Forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.Human Chorionic Gonadotropin (hCG) Key Market Segments :By TechnologyNatural Source ExtractionRecombinant TechnologyBy Therapeutic AreaFemale Infertility TreatmentMale HypogonadismOligospermic TreatmentOthersBy End UserFertility ClinicsResearch InstitutionsOthersBy RegionNorth AmericaU.S.CanadaMexicoEuropeGermanyUKFranceRussiaRest of EuropeAsia-PacificJapanChinaIndiaAustraliaRest of Asia-PacificLAMEABrazilTurkeySouth AfricaSaudi ArabiaRest of LAMEAKEY MARKET PLAYERSBristol Myers Squibb CompanyMerck & Co., Inc.Ferring B.V.Fresenius Kabi AGCignaSun Pharmaceutical Industries Ltd.Lee BioSolutions, Inc.SanzymeScripps LaboratoriesLupinThe other players in the value chain include (profiles not included in the report):Kamiya Biomedical CompanyIntas PharmaceuticalsProspec-Tany Technogene Ltd.Cipla LimitedBiocare Medical LLCMyBioSourceZydus CadilaLife Medicare & Biotech Pvt. Ltd.Download the full report: About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +1 (718) 213 4904 Website:

Cision View original content:

SOURCE ReportBuyer

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store